Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Cancer Manag Res. 2009 Sep 8;1:107-17.

Bortezomib in the management of multiple myeloma.

Author information

  • 1Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA.

Abstract

Multiple myeloma (MM) is a B-cell malignancy characterized by clonal expansion of plasma cells within the bone marrow, the presence of a serum and/or urine monoclonal protein, lytic bone lesions, and anemia. On a cellular level, the disease is characterized by complex interactions between tumor cells and the surrounding bone marrow microenvironment. Understanding of the relationship between malignant plasma cells and the microenvironment has sparked ongoing efforts to develop targeted therapeutic agents for treatment of this disease. The successful development of the first-in-class small-molecule proteasome inhibitor bortezomib occurred as a result of these efforts. This review focuses on the rationale for bortezomib therapy in the treatment of patients with newly diagnosed and relapsed MM, important treatment-related side effects, and future directions for use of bortezomib and other, emerging proteasome inhibitors.

KEYWORDS:

bortezomib; multiple myeloma; peripheral neuropathy; stem cell transplantation

PMID:
21188129
[PubMed]
PMCID:
PMC3004671
Free PMC Article

Images from this publication.See all images (1)Free text

Figure 1
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Dove Medical Press Icon for PubMed Central
    Loading ...
    Write to the Help Desk